Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00:02 2023-02-03 pm EST
164.61 USD   -0.56%
02/02Johnson & Johnson to Participate in the Cowen 43rd Annual HealthCare Conference
BU
02/02Avalon GloboCare Partnerships, Completed Capital Raise, And Robust IP Portfolio Expose An Attractive Value Proposition ($ALBT)
AQ
02/02Formycon Licenses Stelara Biosimilar Candidate to Fresenius Unit
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Credit Suisse Starts Johnson & Johnson at Neutral With $170 Price Target

11/18/2022 | 08:08am EST


ę MT Newswires 2022
All news about JOHNSON & JOHNSON
02/02Johnson & Johnson to Participate in the Cowen 43rd Annual HealthCare Conference
BU
02/02Avalon GloboCare Partnerships, Completed Capital Raise, And Robust IP Portfolio Expose ..
AQ
02/02Formycon Licenses Stelara Biosimilar Candidate to Fresenius Unit
MT
01/31Moody's Says Johnson & Johnson's Court Loss is Negative Credit Development
MT
01/31Federal Appellate Court Rejects Controversial J&J Ploy to Dodge Talc Cancer Lawsuits
PR
01/31With Multiple Shots On Revenue-Generating Goals, Avalon GloboCare Positions For A Break..
AQ
01/31Solid results for Pets at home and UBS: MarketScree..
MS
01/31Idorsia Files European Marketing Authorization Application For Resistant Hypertension T..
MT
01/30Federal Appellate Court Rejects Controversial J&J Ploy to Dodge Talc Cancer Lawsuits
PR
01/30Sector Update: Health Care Stocks' Losses Gain Speed Near Monday Close
MT
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 017 M - -
Net income 2022 20 668 M - -
Net cash 2022 10 806 M - -
P/E ratio 2022 20,7x
Yield 2022 2,68%
Capitalization 430 B 430 B -
EV / Sales 2022 4,42x
EV / Sales 2023 4,18x
Nbr of Employees 141 700
Free-Float 83,8%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 164,61 $
Average target price 180,90 $
Spread / Average Target 9,90%
EPS Revisions
Managers and Directors
Joaquin Duato Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
James D. Swanson Global Chief Information Officer & Executive VP
Dan Zelem Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-6.29%430 370
ELI LILLY AND COMPANY-9.61%322 186
NOVO NORDISK A/S0.37%309 611
ROCHE HOLDING AG-2.81%269 030
MERCK & CO., INC.-7.22%260 994
ABBVIE INC.-10.15%256 696